Graham Dellaire (@docdellaire.bsky.social)

In vivo CAR engineering for immunotherapy - Nature Reviews Immunology In vivo chimeric antigen receptor (CAR) engineering has emerged as a promising off-the-shelf therapeutic approach for hard-to-treat diseases such as solid tumours, offering key advantages such as streamlined production, the elimination of patient-specific manufacturing, reduced costs and simplified logistics. In this Review, Yang and colleagues provide an overview of current in vivo CAR engineering strategies, highlighting existing challenges and discussing future directions for the field. https://www.nature.com/articles/s41577-025-01174-1